[Decrease of paraprotein secretion despite progressive tumor cell proliferation by cytostatic drug therapy of plasmacytoma].
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001842:Bone and Bones / Q000000981:diagnostic imaging; D003520:Cyclophosphamide / Q000008:administration & dosage; D006801:Humans; D007136:Immunoglobulins / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000000981:diagnostic imaging / Q000188:drug therapy*; D009277:Nandrolone / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077603:Nandrolone Decanoate; D010265:Paraproteinemias / Q000188:drug therapy*; D011241:Prednisone / Q000008:administration & dosage; D011877:Radionuclide Imaging; D014750:Vincristine / Q000008:administration & dosage
D007136:Immunoglobulins; D014750:Vincristine; D009277:Nandrolone; D003520:Cyclophosphamide; D000077603:Nandrolone Decanoate; D011241:Prednisone
Abnahme der Paraproteinsekretion trotz progredienter Tumorzellproliferation unter Zytostatikatherapie eines Plasmozytoms.